Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations

Sickle cell disease (SCD) is a monogenic hemoglobinopathy with inequities in morbidity and care within and between countries. Prenatal somatic gene therapy is proposed but remains preclinical for SCD. This critical narrative review examines how such an intervention would interact with existing disparities and evaluates it in terms of autonomy, beneficence, non‐maleficence, and justice. SCD differs from conditions for which fetal intervention is established: fetal hemoglobin is protective, clinical manifestations generally arise after its postnatal decline, and newborn screening permits early preventive care. A prenatal intervention must therefore demonstrate a material advantage over timely postnatal management while exposing neither the pregnant person nor fetus to disproportionate procedural or product risk. Intended somatic treatment is not equivalent to heritable genome editing or embryo selection, although off‐target effects, mosaicism and unintended germline exposure require explicit investigation. There is currently no evidence that prenatal somatic gene therapy is cost‐effective or would overcome access barriers. Its reliance on fetal medicine, molecular, and manufacturing infrastructure could initially widen disparities. Clinical translation would be ethically defensible only after disease‐specific comparative evidence, independent oversight, non‐directive consent, lifelong follow‐up and a credible equitable‐access plan. Strengthening newborn screening and proven care remains the immediate justice priority.

Authors

Institutions

Publication Details

Journal
Prenatal Diagnosis
Published
2026-11-21
DOI
https://doi.org/10.1002/pd.70314
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations

Annarita Miccio, John Strouboulis, Panicos Shangaris, María Teresa Martín Monreal et al.
Prenatal Diagnosis
Hemoglobinopathies and Related Disorders
article

Prenatal Genetics and Investigational in Utero Gene Therapy for Sickle Cell Disease: Clinical, Ethical, and Justice Considerations

Annarita Miccio, John Strouboulis, Panicos Shangaris, María Teresa Martín Monreal, Evangelia Vlachodimitropoulou, Sara El Hoss, Eugene Oteng‐Ntim, Kypros H. Nicolaides, Ciro Chiappini, Leila Sallie, Morgan Bell-Ricketts Bell-Ricketts, Lisa Joy Kaiser, Alexandros Abdel Massih, Aurora Riolini, Saffron Rai, Zuzanna Ammar
article en

Abstract

Sickle cell disease (SCD) is a monogenic hemoglobinopathy with inequities in morbidity and care within and between countries. Prenatal somatic gene therapy is proposed but remains preclinical for SCD. This critical narrative review examines how such an intervention would interact with existing disparities and evaluates it in terms of autonomy, beneficence, non‐maleficence, and justice. SCD differs from conditions for which fetal intervention is established: fetal hemoglobin is protective, clinical manifestations generally arise after its postnatal decline, and newborn screening permits early preventive care. A prenatal intervention must therefore demonstrate a material advantage over timely postnatal management while exposing neither the pregnant person nor fetus to disproportionate procedural or product risk. Intended somatic treatment is not equivalent to heritable genome editing or embryo selection, although off‐target effects, mosaicism and unintended germline exposure require explicit investigation. There is currently no evidence that prenatal somatic gene therapy is cost‐effective or would overcome access barriers. Its reliance on fetal medicine, molecular, and manufacturing infrastructure could initially widen disparities. Clinical translation would be ethically defensible only after disease‐specific comparative evidence, independent oversight, non‐directive consent, lifelong follow‐up and a credible equitable‐access plan. Strengthening newborn screening and proven care remains the immediate justice priority.

Prenatal Diagnosis
St Thomas' Hospital (GB), Inserm (FR), King's College London (GB), Université Paris Cité (FR), London Centre for Nanotechnology (GB), Harris Birthright Research Centre for Fetal Medicine (GB), Institut des Maladies Génétiques Imagine (FR)
Hemoglobinopathies and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon